Evidence map›Paper›PMID 36000039›Full record

ArticleLaryngoscope investigative otolaryngology2022

Clinical impact of p16 positivity in nasopharyngeal carcinoma.

Yuri Shimizu, Naoya Murakami, Taisuke Mori, Kana Takahashi, Yuko Kubo, Seiichi Yoshimoto, Yoshitaka Honma, Satoshi Nakamura, Hiroyuki Okamoto, Kotaro Iijima and 8 more

Open access · goldAbstract read
In one paragraph

Article in Laryngoscope investigative otolaryngology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Clinical impact of p16 positivity in nasopharyngeal carcinoma.Laryngoscope investigative otolaryngology · 2022
    Article
  10. P16 protein Expression in Nasopharyngeal Carcinoma Histologic Subtypes in Kano.Nigerian medical journal : journal of the Nigeria Medical Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Yuri ShimizuDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.ORCID https://orcid.org/0000-0002-9094-2637
Naoya MurakamiDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.ORCID https://orcid.org/0000-0003-0660-9987
Taisuke MoriDepartment of Diagnostic Pathology National Cancer Center Hospital Tokyo Japan.
Kana TakahashiDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Yuko KuboDepartment of Diagnostic Radiology National Cancer Center Hospital Tokyo Japan.
Seiichi YoshimotoDepartment of Head and Neck Surgery National Cancer Center Hospital Tokyo Japan.
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology National Cancer Center Hospital Tokyo Japan.
Satoshi NakamuraRadiation Safety and Quality Assurance Division National Cancer Center Hospital Tokyo Japan.
Hiroyuki OkamotoRadiation Safety and Quality Assurance Division National Cancer Center Hospital Tokyo Japan.
Kotaro IijimaRadiation Safety and Quality Assurance Division National Cancer Center Hospital Tokyo Japan.
Ayaka TakahashiDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Tomoya KanedaDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Tairo KashiharaDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Koji InabaDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Kae OkumaDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Yuko NakayamaDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Hiroshi IgakiDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Jun ItamiDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.
Tokyo National Hospital · JPShinmatsudo Central General Hospital · JPNational Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The clinical characteristics and prognosis of HPV-related nasopharyngeal cancer (NPC) remain controversial. The relationship between p16 status and outcome was retrospectively investigated in the NPC patients. Materials and Methods: Between May 2009 and May 2019, 81 NPC patients who received definitive radiation therapy, in a hospital in Japan, were identified and the prognosis was investigated. p16, p53, and Epstein-Barr virus (EBV) status were assessed. Also, circumferential tumor extent in the nasopharyngeal cavity was assessed on a 5-point scale. Results: Nine and 72 patients were p16-positive and p16-negative, respectively. Fewer patients were EBV-encoded RNA in situ hybridization (EBER-ISH)-positive in the p16-positive group than in the p16-negative group ( Conclusion: In this study conducted in Japan, p16-positive NPC patients are minor but not very low, and the proportion of keratinizing NPCs was small. p16-positive NPCs were seen both in keratinizing and nonkeratinizing NPCs. P16-positive NPC had a tendency of better PFS than p16-negative NPC. This better prognosis might be due to the higher radiosensitivity of the p16-positive cell. Additionally, p16-positive NPCs seemed to spread more extensively in circumference along the nasopharyngeal mucosa than p16-negative NPCs.

Indexed as

head and neckHPVnasopharyngeal cancerp16radiation therapy

Identifiers

PMID36000039
PMCPMC9392382
OpenAlexW4282935689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.